The 36-month beta value for ZNTL is also noteworthy at 1.71. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for ZNTL is 61.39M, and at present, short sellers hold a 12.48% of that float. The average trading volume of ZNTL on October 30, 2024 was 1.81M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ZNTL) stock’s latest price update
The stock price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) has jumped by 0.35 compared to previous close of 2.83. Despite this, the company has seen a fall of -8.97% in its stock price over the last five trading days. gurufocus.com reported 2024-10-07 that FMR LLC (Trades, Portfolio), a prominent investment firm, recently adjusted its holdings in Zentalis Pharmaceuticals Inc (ZNTL, Financial), a clinical-stage biopharmaceutical company. On September 30, 2024, FMR LLC (Trades, Portfolio) reduced its position by 3,600,886 shares, resulting in a new total of 5,075,837 shares.
ZNTL’s Market Performance
ZNTL’s stock has fallen by -8.97% in the past week, with a monthly drop of -22.83% and a quarterly drop of -26.99%. The volatility ratio for the week is 9.00% while the volatility levels for the last 30 days are 6.50% for Zentalis Pharmaceuticals Inc The simple moving average for the last 20 days is -7.30% for ZNTL’s stock, with a simple moving average of -66.60% for the last 200 days.
Analysts’ Opinion of ZNTL
Many brokerage firms have already submitted their reports for ZNTL stocks, with Wedbush repeating the rating for ZNTL by listing it as a “Neutral.” The predicted price for ZNTL in the upcoming period, according to Wedbush is $4 based on the research report published on August 12, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see ZNTL reach a price target of $5, previously predicting the price at $28. The rating they have provided for ZNTL stocks is “Neutral” according to the report published on June 20th, 2024.
ZNTL Trading at -14.28% from the 50-Day Moving Average
After a stumble in the market that brought ZNTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.43% of loss for the given period.
Volatility was left at 6.50%, however, over the last 30 days, the volatility rate increased by 9.00%, as shares sank -20.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.48% lower at present.
During the last 5 trading sessions, ZNTL fell by -8.97%, which changed the moving average for the period of 200-days by -80.08% in comparison to the 20-day moving average, which settled at $3.06. In addition, Zentalis Pharmaceuticals Inc saw -81.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZNTL starting from Vultaggio Vincent, who sale 1,603 shares at the price of $3.18 back on Oct 04 ’24. After this action, Vultaggio Vincent now owns 33,855 shares of Zentalis Pharmaceuticals Inc, valued at $5,098 using the latest closing price.
Gallagher Cam, the President, Interim CFO of Zentalis Pharmaceuticals Inc, sale 9,597 shares at $11.98 during a trade that took place back on May 31 ’24, which means that Gallagher Cam is holding 633,680 shares at $114,972 based on the most recent closing price.
Stock Fundamentals for ZNTL
Current profitability levels for the company are sitting at:
- -5.17 for the present operating margin
- 0.97 for the gross margin
The net margin for Zentalis Pharmaceuticals Inc stands at -4.56. The total capital return value is set at -0.52. Equity return is now at value -42.98, with -34.97 for asset returns.
Based on Zentalis Pharmaceuticals Inc (ZNTL), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -3.78. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -37.06.
Currently, EBITDA for the company is -247.6 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 4.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.59.
Conclusion
In summary, Zentalis Pharmaceuticals Inc (ZNTL) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
